Basic Information
| LncRNA/CircRNA Name | MIR22HG |
| Synonyms | MIR22HG, C17orf91 |
| Region | GRCh38_17:1711493-1717174 |
| Ensemble | ENSG00000186594 |
| Refseq | NR_028502 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR etc. |
| Sample | lung cancer tissues, cell lines (PC-9, H1975, H1299, H838 and H2228) |
| Expression Pattern | down-regulated |
| Function Description | MIR22HG was significantly downregulated in lung cancer;this decreased expression was associated with poor patient survival. MIR22HG bound and stabilized the YBX1 protein.Silencing of MIR22HG triggered both cell survival and cell death signaling through dysregulation of the oncogenes YBX1,MET,and p21. In this MIR22HG network,p21 played an oncogenic role by promoting cell proliferation and anti-apoptosis in lung cancers.MIR22HG played a tumor suppressor role as indicated by inhibition of multiple cell cycle-related genes in human primary lung tumors. |
| Pubmed ID | 29669758 |
| Year | 2018 |
| Title | Silencing of long non-coding RNA MIR22HG triggers cell survival/death signaling via oncogenes YBX1, MET, and p21 in lung cancer. |
External Links
| Links for MIR22HG | GenBank HGNC NONCODE |
| Links for lung cancer | OMIM COSMIC |